Suppr超能文献

抗凝相关肾病:一例病例报告及对一个日益被认识的实体的文献综述

Anticoagulant-related nephropathy: a case report and review of the literature of an increasingly recognized entity.

作者信息

Kalaitzidis Rigas G, Duni Anila, Liapis Georgios, Balafa Olga, Xiromeriti Sofia, Rapsomanikis Paulos Karolos, Elisaf Moses S

机构信息

Department of Nephrology, University Hospital of Ioannina, Ioannina, Greece.

1st Department of Pathology Medical School, National and Kapodistrian University of Athens, Athens, Greece.

出版信息

Int Urol Nephrol. 2017 Aug;49(8):1401-1407. doi: 10.1007/s11255-017-1527-9. Epub 2017 Feb 4.

Abstract

Treatment with oral anticoagulants has been associated with worsening kidney function in patients with chronic kidney disease (CKD) as well as among patients without underlying CKD. Thus, anticoagulant-related nephropathy (ARN) is an increasingly recognized entity nowadays, mainly associated with warfarin anticoagulation. Recent evidence indicates that patients treated with the direct anticoagulants may also be at risk of ARN. However, the true incidence of anticoagulant-related nephropathy is difficult to determine. The typical histological lesion involves renal tubular occlusion by red blood cells (RBCs), tubular red blood cell casts on light microscopy and dysmorphic RBCs in the glomerulus on electron microscopy. In the absence of active glomerulonephritis or other inflammatory changes that could account for glomerular hemorrhage, the above findings confirm the diagnosis. Dabigatran etexilate was the first direct oral anticoagulant approved for stroke prevention in patients with non-valvular atrial fibrillation. In this article, we describe a rare case of dabigatran etexilate-induced nephropathy in a patient with preexisting IgA nephropathy and review the recent literature regarding this increasingly recognized entity.

摘要

口服抗凝剂治疗与慢性肾脏病(CKD)患者以及无潜在CKD的患者肾功能恶化有关。因此,抗凝剂相关肾病(ARN)如今是一个越来越被认可的疾病实体,主要与华法林抗凝有关。最近的证据表明,接受直接抗凝剂治疗的患者也可能有患ARN的风险。然而,抗凝剂相关肾病的真实发病率难以确定。典型的组织学病变包括红细胞(RBC)导致的肾小管阻塞、光镜下的肾小管红细胞管型以及电镜下肾小球内的异形红细胞。在没有活动性肾小球肾炎或其他可解释肾小球出血的炎症改变的情况下,上述发现可确诊。达比加群酯是首个被批准用于非瓣膜性心房颤动患者预防卒中的直接口服抗凝剂。在本文中,我们描述了1例已有IgA肾病的患者发生达比加群酯所致肾病的罕见病例,并回顾了有关这个越来越被认可的疾病实体的近期文献。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验